Michael Barbella, Managing Editor12.11.21
Business news dominated readers' attention this week amid a flurry of acquisitions and partnerships. BD led the pack, revealing the name of its independent, publicly-traded Diabetes Care business ("embecta"), and announcing the purchase of privately-held Tissuemed Ltd., a Leeds, England-based developer of self-adhesive surgical sealant films. The new business name represents BD's commitment to diabetes patients and its corporate heritage: the "em" prefix evokes sympathy for those living with diabetes as well as the empowerment of the new firm to seek new avenues of growth, while the "bect" embodies the BD spirit by embedding part of its legacy brand—the "bect" from Becton, Dickinson and Company.
Other M&A-related news popular with website visitors included Thermo Fisher Scientific's closing of its $17.4 billion PPD deal, a purchase first announced in April. The acquisition is expected to contribute about $1.50 to Thermo Fisher's adjusted earnings per share next year.
The Thermo Fisher-PPD deal closing followed Venus Medtech's $300 million bid for Israeli transcatheter mitral and tricuspid valve treatment company Cardiovalve the previous day (Dec. 7). China-based Venus Medtech said the deal will enhance its product pipeline in the cardiac valve disease treatment area and accelerate its expansion into international markets.
1. BD Chooses 'embecta' for Name of Diabetes Biz Spinoff
2. Thermo Fisher Closes $17.4B Deal for PPD
3. BD Buys Tissuemed, Gains Advanced Surgical Sealant
4. Venus Medtech to Buy Cardiovalve for $300M
5. Dentsply Sirona, 3Shape Expand Strategic Partnership
Other M&A-related news popular with website visitors included Thermo Fisher Scientific's closing of its $17.4 billion PPD deal, a purchase first announced in April. The acquisition is expected to contribute about $1.50 to Thermo Fisher's adjusted earnings per share next year.
The Thermo Fisher-PPD deal closing followed Venus Medtech's $300 million bid for Israeli transcatheter mitral and tricuspid valve treatment company Cardiovalve the previous day (Dec. 7). China-based Venus Medtech said the deal will enhance its product pipeline in the cardiac valve disease treatment area and accelerate its expansion into international markets.
1. BD Chooses 'embecta' for Name of Diabetes Biz Spinoff
2. Thermo Fisher Closes $17.4B Deal for PPD
3. BD Buys Tissuemed, Gains Advanced Surgical Sealant
4. Venus Medtech to Buy Cardiovalve for $300M
5. Dentsply Sirona, 3Shape Expand Strategic Partnership